STOCKHOLM, Nov. 7, 2022
/PRNewswire/ -- Calliditas Therapeutics AB (publ)
("Calliditas") today announced that it will host a Key Opinion
Leader (KOL) Fireside Chat on the IgA Nephropathy (IgAN) treatment
landscape in the US on Tuesday, November
8th, 2022 at 1:30pm Eastern
Time.
The fireside chat will feature a presentation from KOL Richard
Lafayette, M.D., F.A.C.P., Stanford Healthcare, who will discuss
the importance of proteinuria reduction, the recently published
data from Part A of the NefIgArd study, and the existing treatment
paradigm in the United States for
IgAN patients. A live Q&A session will follow the formal
presentations.
To register, please click here.
Dr. Lafayette is Professor of Medicine (Nephrology) and the
Found and Director of the Stanford Glomerular Disease Center and
its fellowship training program at Stanford
University Medical Center. His 25-year career in nephrology
spans general nephrology, transplant nephrology, and focuses on
glomerular disease. During this time, he has served as Senior
Associate Chair of Medicine for six years and Clinical Chief of
Nephrology for more than a decade. Dr. Lafayette was a member of
the first Kidney News Editorial Board and is a member of the ASN
Glomerular Diseases Advisory Group. He earned his medical degree at
New York Medical College, trained in
Internal Medicine at Long Island Jewish Medical Center and in
nephrology at Stanford University.
For further information, please contact:
Marie Galay, IR Manager,
Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on November 7, 2022 at 9:00
a.m. CET.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company
based in Stockholm, Sweden focused
on identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product, developed under the name Nefecon, has been granted
accelerated approval by the FDA under the trade name
TARPEYO® and conditional marketing authorization by the
European Commission under the trade name KINPEYGO®.
KINPEYGO is being commercialized in the European Union Member
States by Calliditas' partner, STADA Arzneimittel AG.
Additionally, Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary
cholangitis and a Phase 2 proof-of-concept trial in head and neck
cancer with its NOX inhibitor product candidate, setanaxib.
Calliditas' common shares are listed on Nasdaq Stockholm (ticker:
CALTX) and its American Depositary Shares are listed on the Nasdaq
Global Select Market (ticker: CALT).
The following files are available for download:
https://mb.cision.com/Main/16574/3662083/1650885.pdf
|
KOL Event
Eng
|
View original
content:https://www.prnewswire.com/news-releases/key-opinion-leader-fireside-chat-with-professor-richard-lafayette-on-the-us-igan-treatment-landscape-301669910.html
SOURCE Calliditas Therapeutics